Antiviral agents for the treatment of COVID-19: Progress and challenges
- PMID: 35474740
- PMCID: PMC8831133
- DOI: 10.1016/j.xcrm.2022.100549
Antiviral agents for the treatment of COVID-19: Progress and challenges
Abstract
The COVID-19 pandemic has seen clinical development and use of antiviral therapies at an unprecedented speed. Antiviral therapies have greatly improved the clinical outcome in COVID-19 patients, especially when administered early after diagnosis. Here, we discuss the successes and challenges of COVID-19 antiviral therapies and lessons for future pandemics.
Conflict of interest statement
The authors declare no competing interests.
Figures
References
-
- Ryu W.S. Molecular Virology of Human Pathogenic Viruses. Elsevier; 2017. Antiviral Therapy; pp. 367–381. - DOI
-
- National Institutes of Health Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2021. https://www.covid19treatmentguidelines.nih.gov/ - PubMed
-
- Regulatory Affairs Professionals Society COVID-19 therapeutics tracker. 2021. https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-the...
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
